Alzheimer’s disease treatments for genetically at-risk patients
This article was originally published in Start Up
Martin Tolar, a neurologist and neuroscientist by training and longtime AD R&D leader and dealmaker, believes that tramiprosate, a red-algae derivative that failed Phase III trials in 2007, had, in fact, significant disease-modifying benefit for a specific subset, but still a majority, of patients in the study. He founded Alzheon Inc. around a prodrug of tramiprosate and related intellectual property to pursue what he sees as a high-speed, low-cost pathway to test whether trampirosate could become the first approved AD drug in more than a decade – and the first personalized to a genetically identifiable patient population.
You may also be interested in...
New data for Alzheon's Alzheimer's disease drug, tramiprosate, from two Phase III trials that failed to show efficacy in 2007 may shed light on how the company can better design new trials for follow-on product ALZ-801, for which it will initiate pivotal Phase III studies next year.
Phase III data presented in Athens shows clinical benefit for cognition and/or function in patients who are homozygous or heterozygous for the APOE4 gene.
Alzheimer’s disease science is in disarray and the risk associated with developing disease-modifying agents has driven many players from the field. But venturesome biotechs are finding backers to support efforts to look for a way forward: we profile Alzheon Inc., Neurotrack Inc., Rodin Therapeutics Inc., and Tetra Discovery Partners LLC.